An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2023.2178409
Abstract: ABSTRACT Introduction Regular blood transfusions in patients with thalassemia syndromes can cause iron overload resulting in complications including cirrhosis, heart problems, or endocrine abnormalities. To prevent iron overload toxicity in these patients, three iron chelators… read more here.
Keywords: thalassemia syndromes; iron overload; transfusional iron; iron ... See more keywords
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006778
Abstract: Key Points • Long-term deferiprone therapy was not associated with new safety concerns in patients with SCD or other anemias.• Long-term deferiprone therapy led to continued and progressive reduction in iron load in patients with… read more here.
Keywords: iron overload; transfusional iron; overload sickle; iron ... See more keywords